Financhill
Sell
35

MRK Quote, Financials, Valuation and Earnings

Last price:
$94.53
Seasonality move :
3.5%
Day range:
$93.45 - $94.88
52-week range:
$81.04 - $134.63
Dividend yield:
3.3%
P/E ratio:
14.05x
P/S ratio:
3.74x
P/B ratio:
5.16x
Volume:
12.7M
Avg. volume:
18.3M
1-year change:
-21.53%
Market cap:
$238.9B
Revenue:
$64.2B
EPS (TTM):
$6.73

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MRK
Merck &
$16.1B $2.18 -1.15% 13.5% $112.29
AMGN
Amgen
$8.9B $5.34 8.14% 257.4% $315.95
GILD
Gilead Sciences
$6.9B $1.93 1.18% 49.16% $111.26
MRNA
Moderna
$121.2M -$3.08 -19.37% -0.05% $54.40
REGN
Regeneron Pharmaceuticals
$3.6B $10.51 9.12% 53% $923.05
VKTX
Viking Therapeutics
-- -$0.36 -- -21.87% $99.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MRK
Merck &
$94.57 $112.29 $238.9B 14.05x $0.81 3.3% 3.74x
AMGN
Amgen
$313.71 $315.95 $168.5B 41.55x $2.38 2.91% 5.07x
GILD
Gilead Sciences
$111.44 $111.26 $138.8B 301.19x $0.79 2.78% 4.87x
MRNA
Moderna
$34.62 $54.40 $13.4B -- $0.00 0% 4.20x
REGN
Regeneron Pharmaceuticals
$666.87 $923.05 $72.9B 17.42x $0.88 0.13% 5.40x
VKTX
Viking Therapeutics
$30.89 $99.29 $3.5B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MRK
Merck &
44.49% 0.543 15.58% 0.84x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
GILD
Gilead Sciences
58.02% 0.435 23.22% 1.33x
MRNA
Moderna
-- 0.488 -- 3.45x
REGN
Regeneron Pharmaceuticals
6.33% 0.941 2.54% 3.86x
VKTX
Viking Therapeutics
-- -1.225 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MRK
Merck &
$11.8B $4.3B 21.67% 40.25% 28.79% $2.5B
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
GILD
Gilead Sciences
$6B $2.4B 1.09% 2.5% 31.92% $2.8B
MRNA
Moderna
$217M -$1.2B -29.09% -29.09% -123.22% $303M
REGN
Regeneron Pharmaceuticals
$3.2B $1B 14.73% 15.78% 25.56% $995.8M
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$31.2M

Merck & vs. Competitors

  • Which has Higher Returns MRK or AMGN?

    Amgen has a net margin of 23.96% compared to Merck &'s net margin of 6.9%. Merck &'s return on equity of 40.25% beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.5% $1.48 $83.5B
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About MRK or AMGN?

    Merck & has a consensus price target of $112.29, signalling upside risk potential of 18.73%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could grow by 0.71%. Given that Merck & has higher upside potential than Amgen, analysts believe Merck & is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    11 10 0
    AMGN
    Amgen
    9 14 2
  • Is MRK or AMGN More Risky?

    Merck & has a beta of 0.348, which suggesting that the stock is 65.24% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock MRK or AMGN?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.3%. Amgen offers a yield of 2.91% to investors and pays a quarterly dividend of $2.38 per share. Merck & pays 45.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

  • Which has Better Financial Ratios MRK or AMGN?

    Merck & quarterly revenues are $15.6B, which are larger than Amgen quarterly revenues of $9.1B. Merck &'s net income of $3.7B is higher than Amgen's net income of $627M. Notably, Merck &'s price-to-earnings ratio is 14.05x while Amgen's PE ratio is 41.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.74x versus 5.07x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.74x 14.05x $15.6B $3.7B
    AMGN
    Amgen
    5.07x 41.55x $9.1B $627M
  • Which has Higher Returns MRK or GILD?

    Gilead Sciences has a net margin of 23.96% compared to Merck &'s net margin of 23.56%. Merck &'s return on equity of 40.25% beat Gilead Sciences's return on equity of 2.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.5% $1.48 $83.5B
    GILD
    Gilead Sciences
    79.11% $1.42 $46B
  • What do Analysts Say About MRK or GILD?

    Merck & has a consensus price target of $112.29, signalling upside risk potential of 18.73%. On the other hand Gilead Sciences has an analysts' consensus of $111.26 which suggests that it could fall by -0.16%. Given that Merck & has higher upside potential than Gilead Sciences, analysts believe Merck & is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    11 10 0
    GILD
    Gilead Sciences
    15 11 0
  • Is MRK or GILD More Risky?

    Merck & has a beta of 0.348, which suggesting that the stock is 65.24% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

  • Which is a Better Dividend Stock MRK or GILD?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.3%. Gilead Sciences offers a yield of 2.78% to investors and pays a quarterly dividend of $0.79 per share. Merck & pays 45.8% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

  • Which has Better Financial Ratios MRK or GILD?

    Merck & quarterly revenues are $15.6B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Merck &'s net income of $3.7B is higher than Gilead Sciences's net income of $1.8B. Notably, Merck &'s price-to-earnings ratio is 14.05x while Gilead Sciences's PE ratio is 301.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.74x versus 4.87x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.74x 14.05x $15.6B $3.7B
    GILD
    Gilead Sciences
    4.87x 301.19x $7.6B $1.8B
  • Which has Higher Returns MRK or MRNA?

    Moderna has a net margin of 23.96% compared to Merck &'s net margin of -117.16%. Merck &'s return on equity of 40.25% beat Moderna's return on equity of -29.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.5% $1.48 $83.5B
    MRNA
    Moderna
    22.7% -$2.91 $10.9B
  • What do Analysts Say About MRK or MRNA?

    Merck & has a consensus price target of $112.29, signalling upside risk potential of 18.73%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    11 10 0
    MRNA
    Moderna
    5 17 1
  • Is MRK or MRNA More Risky?

    Merck & has a beta of 0.348, which suggesting that the stock is 65.24% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

  • Which is a Better Dividend Stock MRK or MRNA?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.3%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 45.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MRK or MRNA?

    Merck & quarterly revenues are $15.6B, which are larger than Moderna quarterly revenues of $956M. Merck &'s net income of $3.7B is higher than Moderna's net income of -$1.1B. Notably, Merck &'s price-to-earnings ratio is 14.05x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.74x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.74x 14.05x $15.6B $3.7B
    MRNA
    Moderna
    4.20x -- $956M -$1.1B
  • Which has Higher Returns MRK or REGN?

    Regeneron Pharmaceuticals has a net margin of 23.96% compared to Merck &'s net margin of 24.22%. Merck &'s return on equity of 40.25% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.5% $1.48 $83.5B
    REGN
    Regeneron Pharmaceuticals
    85.08% $8.06 $31.3B
  • What do Analysts Say About MRK or REGN?

    Merck & has a consensus price target of $112.29, signalling upside risk potential of 18.73%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 38.42%. Given that Regeneron Pharmaceuticals has higher upside potential than Merck &, analysts believe Regeneron Pharmaceuticals is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    11 10 0
    REGN
    Regeneron Pharmaceuticals
    12 6 0
  • Is MRK or REGN More Risky?

    Merck & has a beta of 0.348, which suggesting that the stock is 65.24% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

  • Which is a Better Dividend Stock MRK or REGN?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.3%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Merck & pays 45.8% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MRK or REGN?

    Merck & quarterly revenues are $15.6B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Merck &'s net income of $3.7B is higher than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Merck &'s price-to-earnings ratio is 14.05x while Regeneron Pharmaceuticals's PE ratio is 17.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.74x versus 5.40x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.74x 14.05x $15.6B $3.7B
    REGN
    Regeneron Pharmaceuticals
    5.40x 17.42x $3.8B $917.7M
  • Which has Higher Returns MRK or VKTX?

    Viking Therapeutics has a net margin of 23.96% compared to Merck &'s net margin of --. Merck &'s return on equity of 40.25% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.5% $1.48 $83.5B
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About MRK or VKTX?

    Merck & has a consensus price target of $112.29, signalling upside risk potential of 18.73%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 221.44%. Given that Viking Therapeutics has higher upside potential than Merck &, analysts believe Viking Therapeutics is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    11 10 0
    VKTX
    Viking Therapeutics
    9 1 0
  • Is MRK or VKTX More Risky?

    Merck & has a beta of 0.348, which suggesting that the stock is 65.24% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

  • Which is a Better Dividend Stock MRK or VKTX?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.3%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 45.8% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MRK or VKTX?

    Merck & quarterly revenues are $15.6B, which are larger than Viking Therapeutics quarterly revenues of --. Merck &'s net income of $3.7B is higher than Viking Therapeutics's net income of -$35.4M. Notably, Merck &'s price-to-earnings ratio is 14.05x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.74x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.74x 14.05x $15.6B $3.7B
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock